Last week our chart of the week was a look at the total number of clinical trials started annually that include biomarkers, with a projection out to 2020.  The hockey stick shape of the growth rate was striking, so much so that we decided to follow-up and ask the question: are there actually new and unique biomarkers being used in these trials, or are the same biomarkers being used again and again?

So this week we ran an analysis out of BiomarkerBase of the number of unique biomarkers that have been measured in clinical trials each year, and the results are pretty remarkable.  Over 700 unique biomarkers were measured in clinical trials started during 2015, and if the current growth rate continues, over 50% more will be used five years from now.

Total_Number_of_Unique_Biomarkers_Used_in_Clinical_Trials_by_Trial_Start_Year.png

Share this Image On Your Site

Please include attribution to amplion.com with this graphic.

DistinctBiomarkersInTrialsByYear.png

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access